Identification of IL-17A-derived Neural Cell Type and Dynamic Changes of IL-17A in Serum/csf of Mice with Ischemic Stroke.

Shujuan Li,Qingqing Dai,Jinling Yu,Ting Liu,Shuiqiao Liu,Longhui Ma,Ying Zhang,Song Han,Junfa Li
DOI: https://doi.org/10.1080/01616412.2017.1315863
2017-01-01
Neurological Research
Abstract:Background: Interleukin (IL)-17A was reported to be involved in the development of post-ischemic stroke inflammatory response and functional recovery. However, the IL-17A dynamic changes in serum/cerebrospinal fluid (CSF) and its role in neuronal injury following ischemic stroke are unclear.Methods:In vivo ischemic stroke was induced by 1h of middle cerebral artery occlusion (MCAO) and 6h-7 d reperfusion (R) in mice, while in vitro stroke was induced by 1h oxygen-glucose deprivation (OGD)/24h reoxygenation (R) in cultured cortical neurons. Enzyme-linked immunosorbent assay (ELISA) and double-labeled immunofluorescence of IL-17A with neuron (NeuN), astrocyte (GFAP) and microglia (Iba-1)-specific markers were used to determine the IL-17A levels in serum/CSF and neural cell type.Results: The ELISA results showed that IL-17A significantly increased both in peri-infarct region (p < 0.001) and CSF (p < 0.05) following 1h MCAO/R 12h. The levels of IL-17A in serum increased at R 1d (p < 0.05) and peaked at R 3d (p < 0.001) after 1h MCAO. Immunofluorescent staining demonstrated that IL-17A co-localized with GFAP in peri-infarct regions. In addition, recombinant rIL-17A could aggravate ischemic injuries at dose-dependent manner in 1h OGD/R 24h-treated neurons companying with the increase of IL-17A receptor il-17RA mRNA (p < 0.001) and IL-17R protein levels.Conclusion: We firstly reported astrocytic IL-17A peaks in CSF within 12h and in serum at 3 d reperfusion after ischemic stroke. IL-17A may exaggerate neuronal injuries through its receptor IL-17R at early stage of ischemic stroke.
What problem does this paper attempt to address?